Adrienne Tinana, MD
Allergy & Immunology · Corpus Christi, TXNPI 1225246747
Payments from drug & device makers
Across 418 payments — averaging $144.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$52K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$812
- CSL Behring$775
- Takeda Pharmaceuticals U.S.A., Inc.$700
- Novartis$412
- plus $3K from 33 others
What the payments were for
- Consulting fees$3,2885%
- Speaking & faculty fees$42,70071%
- Travel & lodging$2,7835%
- Food & beverage$11,39219%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 133 | $52,371 |
| Sanofi | 38 | $2,179 |
| Regeneron Healthcare Solutions, Inc. | 37 | $812 |
| CSL Behring | 36 | $775 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $700 |
| Novartis | 11 | $412 |
| GSK | 15 | $403 |
| Galderma Laboratories, L.p. | 15 | $392 |
| Amgen(2 entities) | 12 | $227 |
| Genentech USA, Inc. | 7 | $190 |
| Incyte Corporation | 7 | $188 |
| Sanofi-aventis U.S. LLC | 3 | $135 |
| Biocryst US Sales Co., LLC | 4 | $127 |
| Alk-abello, Inc | 8 | $125 |
| Melinta Therapeutics, LLC | 1 | $122 |
| Verona Pharma, Inc. | 1 | $117 |
| Blueprint Medicines Corporation | 2 | $116 |
| Pfizer | 4 | $108 |
| Pharming Healthcare, Inc. | 6 | $106 |
| Optinose US, Inc. | 5 | $97 |
| Octapharma USA, Inc. | 3 | $69 |
| Grifols USA, LLC | 3 | $60 |
| Genentech, Inc. | 1 | $52 |
| Lilly USA, LLC | 2 | $51 |
| LEO Pharma Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $46 |
| Merck | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $34 |
| Mylan Specialty L.p. | 1 | $34 |
| Phadia US Inc. | 2 | $34 |
| Organon | 2 | $30 |
| USWM, LLC | 1 | $25 |
| Advanced Respiratory, Inc | 2 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Kaleo, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,378 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 73 | $506,560 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $261,182 |
| XolairOmalizumab | 63 | $182,094 |
| Dupixent SyringeDupilumab | 25 | $99,944 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $19,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,992 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $15,474 |
| Epinephrine | 53 | $11,093 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $10,934 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $8,931 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,385 |
| DuleraMometasone/Formoterol | 11 | $4,177 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 28 | $3,688 |
| Azelastine Hcl | 108 | $3,216 |
| Ipratropium Bromide | 55 | $1,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $700 | $506,56073 claims |
| CSL BehringHizentra | $775 | $261,18232 claims |
| Genentech, Inc.Xolair | $52 | $182,09463 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $403 | $37,82451 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $52,371 | $26,40837 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $11,09353 claims |
| MerckDulera | $42 | $4,17711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Corpus Christi
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
- Erika GonzalezSan Antonio$2.2M
- Richard WassermanDallas$1.9M
- Joseph DiazSan Antonio$1.8M
- Niran AmarWaco$840K
- Robert JacobsSan Antonio$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.